Paper no. 27 in the series ‘High Relaxivity Gadolinium MRI Agents’; for the previous paper in the series see Werner et al. (1).
Full Paper
Effect of a mesitylene-based ligand cap on the relaxometric properties of Gd(III) hydroxypyridonate MRI contrast agents†
Article first published online: 16 OCT 2009
DOI: 10.1002/cmmi.281
Copyright © 2009 John Wiley & Sons, Ltd.
Additional Information
How to Cite
Werner, E. J., Botta, M., Aime, S. and Raymond, K. N. (2009), Effect of a mesitylene-based ligand cap on the relaxometric properties of Gd(III) hydroxypyridonate MRI contrast agents. Contrast Media Mol Imaging, 4: 220–229. doi: 10.1002/cmmi.281
- †
Publication History
- Issue published online: 16 OCT 2009
- Article first published online: 16 OCT 2009
- Manuscript Accepted: 25 JUL 2009
- Manuscript Revised: 24 JUL 2009
- Manuscript Received: 11 JUN 2009
Funded by
- NIH, Berkeley. Grant Number: HL69832
- NATO, Torino. Grant Number: PST.CLG.980380
- MIUR, Torino. Grant Number: PRIN2005:2005039914
- Abstract
- References
- Cited By
Keywords:
- hydroxypyridinone (HOPO);
- mesityl;
- gadolinium;
- MRI contrast agent;
- relaxivity;
- aggregation
Abstract
A series of new Gd(III) hydroxypyridonate complexes featuring a mesitylene (ME)-derived ligand cap has been prepared. Relaxometric characterization reveals that the complexes tend to form large aggregates in solution with slow tumbling rates, as estimated from NMRD analysis, and unique pH-dependent relaxivities. The solution behavior and relaxometric properties are compared with those observed for analogous TREN-capped compounds, and the potential for use of these new ME-capped complexes as pH-responsive MRI contrast agents is explored. Copyright © 2009 John Wiley & Sons, Ltd.

1555-4317/asset/CMMI_left.gif?v=1&s=a8a6a48b20d2aa33fd8b321c57ae1cb0bc0594d3)
1555-4317/asset/CMMI_right.gif?v=1&s=701ce50d1e6ce668ddd14d2e3fae002bfec139d2)
1555-4317/asset/cover.gif?v=1&s=903d040d3e85ebe66678d762234b5b2540b57390)